Challenges of Empirical Antibiotic Therapy for Community-Acquired Pneumonia in Children
1Department of Zoology, University of Oxford, Oxford, United Kingdom.
Insights
Community-acquired pneumonia (CAP) in children requires effective treatment. While empirical antibiotics are often necessary, improving diagnostics and public health infrastructure can combat antibiotic resistance and reduce disease burden globally.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Community-acquired pneumonia (CAP) is a major global cause of child mortality, particularly in those under five.
- Diagnostic challenges in pediatric CAP necessitate broad-spectrum empirical antibiotic use, including penicillins, cephalosporins, and macrolides.
Purpose of the Study:
- To review medical, societal, and political issues surrounding empirical antibiotic use for pediatric CAP in the UK, India, and Nigeria.
- To identify challenges and themes related to empirical antibiotic strategies for CAP in children.
Main Methods:
- Literature review of studies on empirical antibiotic use for pediatric CAP.
- Qualitative analysis of identified themes.
- Analysis based on WHO, BTS, and IDSA guidelines for industrialized and resource-poor settings.
Main Results:
- Poor adherence to antibiotic guidelines observed in the UK.
- Emerging antibiotic resistance to penicillins and macrolides in both developed and developing regions.
- Access to care and treatment challenges identified in Nigeria.
- Vaccination against Streptococcus pneumoniae, Haemophilus influenzae, and measles highlighted as crucial prevention strategies.
Conclusions:
- Empirical antibiotics are evidence-based for CAP treatment in most settings, but better diagnostics and targeted therapy are needed to prevent resistance.
- Improved diagnostics and education can optimize antibiotic use for pediatric CAP.
- Investment in clean water, sanitation, and public health infrastructure is vital to reduce CAP burden in developing countries.
Background:
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality globally, responsible for more than 14% of deaths in children younger than 5 years of age. Due to difficulties with pathogen identification and diagnostics of CAP in children, targeted antimicrobial therapy is not possible, hence the widespread use of empirical antibiotics, in particular penicillins, cephalosporin, and macrolides.
Objectives:
This review aimed to address medical, societal, and political issues associated with the widespread use of empirical antibiotics for CAP in the United Kingdom, India, and Nigeria.
Methods:
A literature review was performed identifying the challenges pertaining to the use of widespread empirical antibiotics for CAP in children. A qualitative analysis of included studies identified relevant themes. Empirical guidance was based on guidelines from the World Health Organization, British Thoracic Society, and Infectious Diseases Society of America, used in both industrialized and resource-poor settings.
Results:
In the United Kingdom there was poor adherence to antibiotics guidelines. There was developing antibiotic resistance to penicillins and macrolides in both developing and industrialized regions. There were difficulties accessing the care and treatment when needed in Nigeria. Prevention strategies with vaccination against Streptococcus pneumonia, Haemophilus influenza, and measles are particularly important in these regions.
Conclusions:
Effective and timely treatment is required for CAP and empirical antibiotics are evidence-based and appropriate in most settings. However, better diagnostics and education to target treatment may help to prevent antibiotic resistance. Ensuring the secure financing of clean food and water, sanitation, and public health infrastructure are also required to reduce the burden of disease in children in developing countries.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:26Urine Studies II: Urine Culture and Sensitivity Test